IMAB Valuation
I-Mab
$
0.000
IMAB Relative Valuation
IMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMAB is overvalued; if below, it's undervalued.
Historical Valuation
-6.22
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
I-Mab. (IMAB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -7.07. The thresholds are as follows: Strongly Undervalued below -35.41, Undervalued between -35.41 and -21.24, Fairly Valued between 7.11 and -21.24, Overvalued between 7.11 and 21.28, and Strongly Overvalued above 21.28. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-10.50
EV/EBIT
I-Mab. (IMAB) has a current EV/EBIT of -10.50. The 5-year average EV/EBIT is -3.06. The thresholds are as follows: Strongly Undervalued below -17.10, Undervalued between -17.10 and -10.08, Fairly Valued between 3.95 and -10.08, Overvalued between 3.95 and 10.97, and Strongly Overvalued above 10.97. The current Forward EV/EBIT of -10.50 falls within the Undervalued range.
4.64
PS
I-Mab. (IMAB) has a current PS of 4.64. The 5-year average PS is 13.52. The thresholds are as follows: Strongly Undervalued below -57.59, Undervalued between -57.59 and -22.03, Fairly Valued between 49.08 and -22.03, Overvalued between 49.08 and 84.64, and Strongly Overvalued above 84.64. The current Forward PS of 4.64 falls within the Historic Trend Line -Fairly Valued range.
-27.65
P/OCF
I-Mab. (IMAB) has a current P/OCF of -27.65. The 5-year average P/OCF is -3.84. The thresholds are as follows: Strongly Undervalued below -117.82, Undervalued between -117.82 and -60.83, Fairly Valued between 53.15 and -60.83, Overvalued between 53.15 and 110.14, and Strongly Overvalued above 110.14. The current Forward P/OCF of -27.65 falls within the Historic Trend Line -Fairly Valued range.
-70.63
P/FCF
I-Mab. (IMAB) has a current P/FCF of -70.63. The 5-year average P/FCF is -13.61. The thresholds are as follows: Strongly Undervalued below -56.61, Undervalued between -56.61 and -35.11, Fairly Valued between 7.89 and -35.11, Overvalued between 7.89 and 29.39, and Strongly Overvalued above 29.39. The current Forward P/FCF of -70.63 falls within the Strongly Undervalued range.
I-Mab (IMAB) has a current Price-to-Book (P/B) ratio of NaN. Compared to its 3-year average P/B ratio of 0.62 , the current P/B ratio is approximately NaN% higher. Relative to its 5-year average P/B ratio of 2.02, the current P/B ratio is about NaN% higher. I-Mab (IMAB) has a Forward Free Cash Flow (FCF) yield of approximately NaN%. Compared to its 3-year average FCF yield of -16.16%, the current FCF yield is approximately NaN% lower. Relative to its 5-year average FCF yield of -12.20% , the current FCF yield is about NaN% lower.
1.93
P/B
Median3y
0.62
Median5y
2.02
0.00
FCF Yield
Median3y
-16.16
Median5y
-12.20
Competitors Valuation Multiple
The average P/S ratio for IMAB's competitors is 10.35, providing a benchmark for relative valuation. I-Mab Corp (IMAB) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IMAB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IMAB in the past 1 year is driven by Unknown.
People Also Watch
ENTX
Entera Bio Ltd
3.140
USD
+0.96%
MVO
MV Oil Trust
4.400
USD
-0.90%
DBVT
Dbv Technologies SA
13.970
USD
-0.50%
ELVA
Electrovaya Inc
5.340
USD
+3.49%
IMUX
Immunic Inc
0.719
USD
+2.42%
AZI
Autozi Internet Technology (Global) Ltd
0.095
USD
-4.05%
AIRG
Airgain Inc
4.080
USD
+0.25%
VOC
VOC Energy Trust
2.885
USD
+1.23%
OSS
One Stop Systems Inc
5.190
USD
-2.81%
FAQ
Is I-Mab (IMAB) currently overvalued or undervalued?
I-Mab (IMAB) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of -13.10. The fair price of I-Mab (IMAB) is between to according to relative valuation methord.
What is I-Mab (IMAB) fair value?
How does IMAB's valuation metrics compare to the industry average?
What is the current P/B ratio for I-Mab (IMAB) as of Nov 09 2025?
What is the current FCF Yield for I-Mab (IMAB) as of Nov 09 2025?
What is the current Forward P/E ratio for I-Mab (IMAB) as of Nov 09 2025?